Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
21 Results for "
lipoprotein metabolism
" in MedChemExpress (MCE) Product Catalog:
Products (21)
21 Results for "lipoprotein metabolism" in MCE Product Catalog:
5
Research Areas:
Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Probucol (DH-581) is an anti-hyperlipidemic agent. Probucol activates glutathione peroxidase. Probucol promotes low density lipoprotein (LDL) catabolism, inhibits ABCA1-dependent cholesterol efflux, and decreases HDL-C levels. Probucol also has anti-inflammatory, antioxidant and neuroprotective properties. Probucol can be used for researches on bone, cardiovascular, cancer, neurological, and metabolism-related diseases .
5
5 Cited Publications
Category:
Human Gut Microbiota Metabolites Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields
Target:
5
Target:
5
5 Cited Publications
Target:
2
2 Cited Publications
Cat. No.: HY-P6306
CAS No.: 1627911-44-7
Target:
Research Areas:
2
2 Cited Publications
Cat. No.: HY-P6306A
Target:
Research Areas:
2
Target:
Research Areas:
Glycerol-3-phosphate oxidase, microorganism is an enzyme that catalyzes the oxidation of glycerol-3-phosphate to dihydroxyacetone phosphate, producing hydrogen peroxide in the process. Glycerol-3-phosphate oxidase is located in the mitochondria of microorganisms and is involved in the glycerol-3-phosphate cycle, regulating cellular energy metabolism. Glycerol-3-phosphate oxidase, microorganism can be used in conjunction with Lipoprotein Lipase and Glycerol Kinase to determine triglyceride levels .
Research Areas:
Colesevelam hydrochloride is an orally active bile acid sequestrant, lipid-lowering agent, and glycemic control agent. Colesevelam hydrochloride binds bile acids in the gastrointestinal tract to form nonabsorbable complexes, interrupts enterohepatic recirculation and increases fecal bile acid elimination. Colesevelam hydrochloride modulates FXR, TGR5, and Cyp7a1 activity and triggers cAMP signaling and GLP-1 release. Colesevelam hydrochloride alters hepatic lipid and glucose metabolism, suppresses hepatic glycogenolysis, reduces hepatic triglyceride and cholesterol levels, and increases LDL-C (low-density lipoprotein cholesterol) clearance. Colesevelam hydrochloride can be used for the research of type 2 diabetes mellitus, hypercholesterolemia, and alcohol-related liver disease .
Target:
Research Areas:
Lipoprotein lipase, Pseudomonas sp (LPL) is a multifunctional enzyme from adipose tissue, heart and skeletal muscle, islets and macrophages. Lipoprotein lipase promotes normal lipoprotein metabolism, delivery and utilization of tissue-specific substrates. Lipoprotein lipase catalyzes the rate-limiting step of lipids in blood circulation .
Target:
Research Areas:
BRD0418 is a diversity-oriented synthesis (DOS) molecule that regulates the expression of tribbles pseudokinase 1. BRD0418 has the effect of causing hot lipoprotein metabolism from fat production to clearance. BRD0418 can be used in the study of coronary artery disease (CAD) .
Cat. No.: HY-163436
CAS No.: 1338190-14-9
Target:
Research Areas:
F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC50 value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders .
Research Areas:
SC-435 is an orally effective apical sodium codependent bile acid transporter (ASBT) inhibitor. SC-435 effectively removes neurotoxic bile acids and ammonia from the blood by inhibiting intestinal ASBT, thereby alleviating liver and brain damage caused by liver failure. SC-435 can alter hepatic cholesterol metabolism and lower plasma low-density lipoprotein-cholesterol concentrations .
Target:
Research Areas:
Tiadenol is an orally effective lipid-lowering compound and peroxisome proliferator. Tiadenol promotes peroxisome-associated fatty acid metabolism, and its induction of the activities of enzymes such as palmitoyl-CoA hydrolase, carnitine acetyl-transferase and catalase is mainly associated with de novo protein synthesis. The triglyceride-lowering effect of Tiadenol is not accompanied by increased activities of lipoprotein lipase (LPL) and hepatic lipase (HL), and it reduces VLDL Apo E. Tiadenol can be used in studies related to lipid metabolism, peroxisome proliferation and hyperlipoproteinemia .
Cat. No.: HY-116977
CAS No.: 69047-39-8
Target:
Research Areas:
Binifibrate is an active compound and has a beneficial effect on lipoprotein metabolism. Binifibrate can be used for the research of hyperlipidemia .
Cat. No.: HY-106278A
CAS No.: 343322-50-9
Target:
Research Areas:
GW 590735 sodium is a potent and selective PPARα agonist with activity in regulating lipid metabolism. GW 590735 significantly increased high-density lipoprotein (HDL) cholesterol, decreased low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) cholesterol, and significantly reduced triglycerides. The maximum increases in HDL cholesterol for GW 590735 were 37%, 53% and 84%, respectively, compared with bezafibrate, torcetrapib and GW 590735 .
Cat. No.: HY-153451
CAS No.: 2455423-94-4
Target:
Research Areas:
PCSK9-IN-15 (compound 5) is a potent inhibitor of proprotein convertase subtilisin/kexin 9 (PCSK9, KD <200 nM). PCSK9 is involved in cholesterol metabolism and regulates levels of low-density lipoprotein cholesterol (LDL-C) in the blood. PCSK9- in -15 can be used to study cholesterol-lowering and dyslipidemia .
Cat. No.: HY-D3398
Target:
Research Areas:
FlavAc is a fluorescent dye (with an excitation wavelength of 980 nm) for real-time in vivo imaging of lipid metabolism disorders, including early fatty liver disease and atherosclerotic plaques. FlavAc specifically integrates into endogenous lipoproteins, primarily low-density lipoprotein (LDL), and shows no brightness enhancement when bound to albumin. FlavAc forms aggregates in aqueous solutions, leading to fluorescence quenching; however, when integrated into lipoproteins, such aggregation decreases, forming stable fluorescent complexes with enhanced brightness. FlavAc can selectively illuminate LDL upon laser irradiation .
Cat. No.: HY-182014
CAS No.: 2408041-54-1
Target:
Research Areas:
TLC-2716 is an orally available, gut- and liver-restricted inhibitor against LXRα and LXRβ, with EC50 values of 7 nM and 15 nM, respectively. TLC-2716 represses LXRα/β transcriptional activity, downregulates genes involved in lipogenesis, lipid absorption and lipoprotein metabolism, and preserves peripheral reverse cholesterol transport. TLC-2716 reduces lipid accumulation, suppresses inflammation and fibrotic gene expression, enhances triglyceride-rich lipoprotein clearance, and improves glucose homeostasis and insulin sensitivity. TLC-2716 lowers serum and hepatic triglycerides, plasma cholesterol and other atherogenic lipid profiles in experimental models and humanized liver mice. TLC-2716 can be used for the research of dyslipidemia and related cardiometabolic disorders .
Cat. No.: HY-201256
CAS No.: 301312-49-2
UCI-14 is a gltA1/lprQ modulator with in vitro anti-tuberculosis activity against drug-sensitive and multidrug-resistant mycobacteria. UCI-14 upregulates the expression of genes encoding citrate synthase I, downregulates the expression of genes encoding conserved mycobacterial lipoprotein, and alters the carbon metabolism of mycobacteria. UCI-14 reactivates the expression of wild-type p53 target genes in p53-mutated cells. UCI-14 can be used in the research of tuberculosis and cancer .
Cat. No.: HY-181876
CAS No.: 3124701-00-1
Target:
Research Areas:
F44-S101 is an orally active, potent, and selective gut-restricted FXR antagonist with an IC50 of 0.48 μM and lipid-lowering activity. F44-S101 selectively antagonizes intestinal FXR, feedback-activates hepatic FXR, promotes cholesterol metabolism and reduces lipid accumulation. F44-S101 decreases total cholesterol, triglyceride and low-density lipoprotein cholesterol levels. F44-S101 can be used in studies related to hyperlipidemia .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
